TXG 10x Genomics, Inc.
TXG 10x Genomics, Inc.
Healthcare · Health Information Services
Desk view
Market read
POC $21.68 · VWAP $36.92 · +93.8% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CEO, CFO + 4 others sold $4.8M, Aug 13–26
Coverage
2 watchlists
TXG Price Structure
Loading timeframes…
Peers
Every watchlist TXG belongs to, members best 30-day change first — TXG highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
@ibb
Decision history
2 scored calls · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
Reported the quarter ending 2026-06-30: revenue $151M, diluted EPS -$0.14, net income -$18M (SEC filing). Across the print the stock moved +9.6% (close before → first close after).
full note →Against street estimates
How TXG's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
News (last pull)
Headlines about TXG from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 17 days ago · Oct 6
- Latest News about 10x Genomics, Inc. - Common Stock (Nasdaq:TXG) | 10x Genomics, Inc. - Common Stock (Nasdaq:TXG) News
- TXG Stock Price (-17.08) | Stock Quote, Chart & News for 10x Genomics on Fox Business
- 10x Genomics Stock Price | TXG Stock Quote, News, and History | Markets Insider
- Investor Relations - 10x Genomics
- 10x Genomics Reports Second Quarter 2026 Financial Results – Company Announcement - FT.com
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
TXG research tape
61 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to TXG.
Vertical: Biotech Capital Cycle — the theme is confirmed; the question is now entries
Obesity/GLP-1 vertical: the next-gen trade is an AI-discovery + tools barbell, not a pure drug-developer bet